International Peptide Laws
Peptide regulations vary significantly worldwide. This guide provides an overview of peptide laws by country and region, covering legal status, regulatory bodies, and import/export considerations.
North America
๐บ๐ธ United States
RestrictedPeptides are restricted in the United States under a two-track system enforced by the Food and Drug Administration (FDA): peptides with FDA-approved drug...
๐จ๐ฆ Canada
RestrictedPeptides in Canada are restricted rather than freely available: Health Canada regulates all peptide drugs as prescription products under its drug authorization...
๐ฒ๐ฝ Mexico
RestrictedPeptides are restricted in Mexico rather than freely sold over the counter: most research/regenerative peptides (e.g., BPC-157, TB-500) are not individually...
๐จ๐ท Costa Rica
RestrictedPeptides in Costa Rica are restricted rather than outright banned as a class: the Ministerio de Salud (Ministry of Health) requires every medicine to hold a...
Europe
๐ฌ๐ง United Kingdom
Gray AreaPeptides occupy a split legal status in the United Kingdom: most research peptides (e.g. BPC-157, TB-500) are unscheduled and legal to possess for research...
๐ช๐บ European Union
RestrictedPeptides are restricted in the European Union rather than freely legal or outright banned as a class: some peptide drugs (semaglutide, tirzepatide,...
๐ฉ๐ช Germany
RestrictedPeptides are restricted in Germany, with legal treatment depending entirely on the specific compound and its intended use. Approved therapeutic peptides such...
๐ณ๐ฑ Netherlands
Gray AreaPeptides in the Netherlands are gray-area substances rather than clearly legal or clearly illegal: the Geneesmiddelenwet (Medicines Act) requires any product...
๐ซ๐ท France
Gray AreaPeptides in France fall into two very different legal buckets, so there is no single blanket verdict. Approved peptide drugs (semaglutide/Ozempic,...
๐ช๐ธ Spain
Gray AreaPeptides in Spain fall into a gray/restricted zone: Spain has no separate 'peptide law,' so their legality depends entirely on whether the specific molecule...
๐ฎ๐น Italy
RestrictedPeptides are restricted in Italy under a two-track system rather than being broadly legal or broadly banned. Medicinal peptides (e.g., semaglutide-class GLP-1...
๐ต๐ฑ Poland
RestrictedPeptides are restricted in Poland under the general Pharmaceutical Law rather than a peptide-specific statute: any substance intended to treat, prevent, or...
๐จ๐ญ Switzerland
RestrictedPeptides are restricted in Switzerland: any substance intended to produce a pharmacological, immunological, or metabolic effect in humans is legally classified...
๐ฌ๐ท Greece
RestrictedPeptides are restricted in Greece rather than freely legal or blanket-banned. The Hellenic Medicines Organization (EOF), following EU/EMA rules, treats GLP-1...
๐ต๐น Portugal
RestrictedPeptides in Portugal are restricted rather than freely legal: the national medicines statute requires that any product presented for a therapeutic purpose...
๐ง๐ช Belgium
Gray AreaPeptides are not illegal as a class in Belgium, but most popular research/compounding peptides (BPC-157, TB-500, ipamorelin, etc.) have no marketing...
๐ธ๐ช Sweden
Gray AreaPeptides in Sweden are legal only when they are approved, prescription-only medicinal products supplied through a pharmacy; unapproved 'research' peptides fall...
๐ฎ๐ช Ireland
Gray AreaPeptides are in a legal gray zone in Ireland: research peptides such as BPC-157 and TB-500 have no marketing authorisation from the Health Products Regulatory...
๐ท๐บ Russia
Gray AreaPeptides in Russia fall into two very different legal buckets: pharmaceutical-grade peptide drugs that have gone through State Registration (like semaglutide...
Asia-Pacific
๐ฆ๐บ Australia
RestrictedPeptides are restricted, not freely legal, in Australia. The Therapeutic Goods Administration (TGA) regulates any product intended for therapeutic use under...
๐ณ๐ฟ New Zealand
RestrictedPeptides are restricted in New Zealand: therapeutic peptides fall under the Medicines Act 1981 framework administered by Medsafe, and products like BPC-157 or...
๐ฏ๐ต Japan
RestrictedPeptides are restricted in Japan under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the PMD Act,...
๐ฐ๐ท South Korea
RestrictedSouth Korea restricts peptide products through the Ministry of Food and Drug Safety (MFDS), which classifies legitimate peptide drugs as prescription...
๐จ๐ณ China
RestrictedPeptides are restricted in China under the general framework of the Pharmaceutical Administration Law, which requires any product marketed, sold, or...
๐ฎ๐ณ India
RestrictedPeptides are not treated in India as a single unified legal category: unapproved research peptides like BPC-157 and TB-500 fall outside any approved drug list...
๐น๐ญ Thailand
Gray AreaPeptides are legal in Thailand only in a split, compound-by-compound way, with the Thai Food and Drug Administration (Thai FDA) and Ministry of Public Health...
๐ธ๐ฌ Singapore
RestrictedPeptides are restricted in Singapore rather than freely legal or outright criminalized for the individual user: Singapore's Health Sciences Authority (HSA)...
๐ฎ๐ฉ Indonesia
Gray AreaPeptides in Indonesia are not covered by a single, peptide-specific law; instead they fall under Indonesia's general medicines framework administered by BPOM...
๐ป๐ณ Vietnam
Gray AreaPeptides are in a regulatory gray area in Vietnam because no publicly verifiable, Vietnam-specific law or Ministry of Health circular naming BPC-157, TB-500,...
๐ต๐ญ Philippines
Gray AreaPeptides are in a legally gray zone in the Philippines because there is no peptide-specific statute; instead, any drug product (including peptides marketed for...
Africa
๐ฟ๐ฆ South Africa
RestrictedPeptides are restricted in South Africa, not freely legal or outright banned across the board. The South African Health Products Regulatory Authority (SAHPRA)...
South America
๐ง๐ท Brazil
RestrictedPeptides are restricted in Brazil, with the national health regulator ANVISA drawing a sharp line between a small number of registered, prescription-only...
๐ฆ๐ท Argentina
RestrictedPeptides are restricted in Argentina: only specific peptide-based drugs formally registered with ANMAT (such as the GLP-1 medicine semaglutide, sold as...
๐จ๐ด Colombia
RestrictedPeptides are restricted in Colombia rather than freely legal or outright banned as a class: the national medicines regulator INVIMA (Instituto Nacional de...
Middle East
๐ฆ๐ช UAE
RestrictedPeptides are restricted in the United Arab Emirates: they are not scheduled as narcotics, but selling or marketing them for human use without MoHAP/EDE drug...
๐ฎ๐ฑ Israel
Gray AreaPeptides are in a legal gray zone in Israel: there is no peptide-specific law naming BPC-157, TB-500, or similar research peptides, so their status is inferred...
๐ธ๐ฆ Saudi Arabia
RestrictedPeptides in Saudi Arabia are restricted rather than freely available: the Saudi Food and Drug Authority (SFDA) treats unapproved 'research peptides' as...
๐น๐ท Turkey
RestrictedPeptides are restricted, not freely legal, in Turkey. Turkey's national medicines regulator, the Tรผrkiye ฤฐlaรง ve Tฤฑbbi Cihaz Kurumu (TฤฐTCK, Turkish...
International Import/Export Considerations
General Principles
- Customs declarations: Most countries require accurate customs declarations for pharmaceutical products
- Personal use exemptions: Some countries allow limited personal imports, others do not
- Documentation: Prescriptions or research documentation may facilitate customs clearance
- Prohibited substances: Some peptides may be classified as controlled substances in certain countries
High-Risk Jurisdictions
Countries with particularly strict enforcement include:
- Australia - strict TGA enforcement, significant import controls
- UAE - strict customs inspection, severe penalties
- Japan - extensive import documentation required
- Singapore - strict pharmaceutical controls
Regulatory Bodies by Region
- North America: FDA (US), Health Canada, COFEPRIS (Mexico)
- Europe: EMA (EU-wide), MHRA (UK), BfArM (Germany)
- Asia-Pacific: TGA (Australia), PMDA (Japan), NMPA (China)
- South America: ANVISA (Brazil), ANMAT (Argentina)